Gene therapy outcomes in young patients with RPE65-retinal degeneration
VN treatment is safe and effective in improving retinal sensitivity in patients 21 years old or less with RPE65-LCA despite the occurrence of CRA post-treatment.
Authors
- Erika Tavares (ORCID: https://orcid.org/0000-0002-5714-1766)
- Gareth Mercer (ORCID: https://orcid.org/0000-0002-9904-6361)
- Brian G. Ballios (ORCID: https://orcid.org/0000-0002-4644-3339)
- K STEPHENSON
- Ajoy Vincent (ORCID: https://orcid.org/0000-0001-6446-3846)
- Abrar K. Alsalamah
- Peter John Kertes
- Elise Héon
- Anupreet Tumber
- Rajeev H Muni
Institutions
- St. Michael's Hospital (CA)
- Sunnybrook Health Science Centre (CA)
- Hospital for Sick Children (CA)
- King Khaled Eye Specialist Hospital (SA)
- Kensington Health (CA)
- SickKids Foundation (CA)
Publication Details
- Journal
- Canadian Journal of Ophthalmology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jcjo.2026.01.016
- Primary Topic
- Retinal Development and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00